Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Adjuvant properties of lipopolysaccharide from Neisseria meningitidis serogroup B detoxified and conjugated with tetanus toxoid.
Vaccine. 2006 Apr 12;24 Suppl 2:S2-63-4. doi: 10.1016/j.vaccine.2005.01.125.
Vaccine. 2006.
PMID: 16823931
Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
Campo JD, Zayas C, Romeu B, Acevedo R, González E, Bracho G, Cuello M, Cabrera O, Balboa J, Lastre M.
Campo JD, et al.
Methods. 2009 Dec;49(4):301-8. doi: 10.1016/j.ymeth.2009.03.025. Epub 2009 May 4.
Methods. 2009.
PMID: 19410000
Item in Clipboard
Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1.
Romeu B, González E, Del Campo J, Acevedo R, Zayas C, Valdés Y, Cabrera O, Cuello M, Balboa J, Lastre M, Pérez O.
Romeu B, et al.
Can J Microbiol. 2011 Mar;57(3):256-61. doi: 10.1139/W11-002.
Can J Microbiol. 2011.
PMID: 21358768
Item in Clipboard
AFCo1 as nasal adjuvant of capsular polysaccharide from Neisseria meningitidis serogroup C induces systemic and mucosal immune responses.
Romeu B, González E, Zayas C, Del Campo J, Acevedo R, Cuello M, Valdes Y, Balboa J, Cabrera O, Lastre M, Pérez O.
Romeu B, et al.
Scand J Infect Dis. 2011 Oct;43(10):809-13. doi: 10.3109/00365548.2011.586648. Epub 2011 Jun 15.
Scand J Infect Dis. 2011.
PMID: 21671827
Item in Clipboard
Pilot scale production of the vaccine adjuvant Proteoliposome derived Cochleates (AFCo1) from Neisseria meningitidis serogroup B.
Zayas C, González D, Acevedo R, del Campo J, Lastre M, González E, Romeu B, Cuello M, Balboa J, Cabrera O, Guilherme L, Pérez O.
Zayas C, et al.
BMC Immunol. 2013;14 Suppl 1(Suppl 1):S4. doi: 10.1186/1471-2172-14-S1-S4. Epub 2013 Feb 25.
BMC Immunol. 2013.
PMID: 23458578
Free PMC article.
Item in Clipboard
The golden era of vaccine adjuvants.
Cabrera O, Cuello M, Lastre M, Romeu B, Balboa J, Zayas C, Pérez O.
Cabrera O, et al.
Expert Rev Vaccines. 2011 Jul;10(7):1007-9. doi: 10.1586/erv.11.62.
Expert Rev Vaccines. 2011.
PMID: 21806395
Item in Clipboard
New vaccines require potent adjuvants like AFPL1 and AFCo1.
Pérez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M, Balboa J, Acevedo R, Zayas C, Gil D, Mora N, González D, Pérez R, González E, Barberá R, Fajardo EM, Sierra G, Solís RL, Campa C.
Pérez O, et al.
Scand J Immunol. 2007 Aug-Sep;66(2-3):271-7. doi: 10.1111/j.1365-3083.2007.01981.x.
Scand J Immunol. 2007.
PMID: 17635804
Free article.
Item in Clipboard
Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations.
Pérez O, Batista-Duharte A, González E, Zayas C, Balboa J, Cuello M, Cabrera O, Lastre M, Schijns VE.
Pérez O, et al.
Braz J Med Biol Res. 2012 Aug;45(8):681-92. doi: 10.1590/s0100-879x2012007500067. Epub 2012 Apr 26.
Braz J Med Biol Res. 2012.
PMID: 22527130
Free PMC article.
Review.
Item in Clipboard
Cite
Cite